Orally administered cannabidiol does not produce false-positive tests for Δ9-tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000,Drug Testing and Analysis

当前位置： X-MOL 学术 › Drug Test. Anal. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Orally administered cannabidiol does not produce false-positive tests for Δ9-tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000
Drug Testing and Analysis ( IF 2.6 ) Pub Date : 2021-08-19 , DOI: 10.1002/dta.3153
Danielle McCartney _{1,

2,

3,

4} , Richard C Kevin _{1,

2,

3} , Anastasia S Suraev _{1,

2,

3,

4} , Christopher Irwin ₅ , Ronald R Grunstein _{4,

6,

7} , Camilla M Hoyos _{2,

3,

4} , Iain S McGregor _{1,

2,

3}

Affiliation

Many jurisdictions use point-of-collection (POC) oral fluid testing devices to identify driving under the influence of cannabis, indexed by the presence of Δ⁹-tetrahydrocannabinol (THC), an intoxicating cannabinoid, in oral fluid. Although the use of the non-intoxicating cannabinoid, cannabidiol (CBD), is not prohibited among drivers, it is unclear whether these devices can reliably distinguish between CBD and THC, which have similar chemical structures. This study determined whether orally administered CBD produces false-positive tests for THC on standard, POC oral fluid testing devices. In a randomised, double-blind, crossover design, healthy participants (n = 17) completed four treatment sessions involving the administration of either placebo or 15-, 300- or 1500-mg pure CBD in a high-fat dietary supplement. Oral fluid was sampled, and the DrugWipe®-5S (DW-5S; 10 ng·ml⁻¹ THC cut-off) and Drug Test® 5000 (DT5000; 10 ng·mL⁻¹ THC cut-off) devices administered, at baseline (pretreatment) and ~20-, ~145- and ~185-min posttreatment. Oral fluid cannabinoid concentrations were measured using ultra-high performance liquid chromatography–tandem mass spectrometry. Median (interquartile range [IQR]) oral fluid CBD concentrations were highest at ~20 min, quantified as 0.4 (6.0), 15.8 (41.6) and 167 (233) ng·ml⁻¹ on the 15-, 300- and 1500-mg CBD treatments, respectively. THC, cannabinol and cannabigerol were not detected in any samples. A total of 259 DW-5S and 256 DT5000 tests were successfully completed, and no THC-positive tests were observed. Orally administered CBD does not appear to produce false-positive (or true-positive) tests for THC on the DW-5S and DT5000. The likelihood of an individual who is using a CBD (only) oral formulation being falsely accused of DUIC therefore appears low.

中文翻译：

口服大麻二酚不会在 Securetec DrugWipe® 5S 或 Dräger DrugTest® 5000 上对 Δ9-四氢大麻酚产生假阳性测试

许多司法管辖区使用收集点 (POC) 口腔液测试设备来识别在大麻影响下的驾驶，以口腔液中 Δ ⁹ -四氢大麻酚 (THC) 的存在为指标，这是一种令人陶醉的大麻素。虽然司机中不禁止使用无毒大麻素大麻二酚 (CBD)，但尚不清楚这些设备是否能可靠地区分具有相似化学结构的 CBD 和 THC。这项研究确定了口服 CBD 是否会在标准 POC 口腔液体检测设备上对 THC 产生假阳性检测。在随机、双盲、交叉设计中，健康参与者（n = 17) 完成了四次治疗，包括在高脂肪膳食补充剂中服用安慰剂或 15、300 或 1500 毫克纯 CBD。对口腔液进行取样，并使用 DrugWipe®-5S（DW-5S；10 ng·ml ^-1 THC 截止值）和 Drug Test® 5000（DT5000；10 ng·mL ^-1 THC 截止值）装置，在基线（预处理）和约 20 分钟、约 145 分钟和约 185 分钟的后处理。使用超高效液相色谱-串联质谱法测量口腔液中的大麻素浓度。中位数（四分位距 [IQR]）口腔液 CBD 浓度在约 20 分钟时最高，量化为 0.4 (6.0)、15.8 (41.6) 和 167 (233) ng·ml ^-1分别在 15、300 和 1500 毫克 CBD 治疗中。在任何样本中均未检测到 THC、大麻酚和大麻酚。共成功完成 259 次 DW-5S 和 256 次 DT5000 测试，未观察到 THC 阳性测试。口服 CBD 似乎不会在 DW-5S 和 DT5000 上对 THC 产生假阳性（或真阳性）测试。因此，使用 CBD（仅）口服制剂的个人被错误地指控为 DUIC 的可能性似乎很低。

更新日期：2021-08-19

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11